Mycophenolate mofetil for myasthenia gravis: A clear and present controversy

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 6, 2008, Pages 1203-1209

  Heatwole, Chad ^a   Ciafaloni, Emma ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

CellCept; Myasthenia gravis; Mycophenolate mofetil

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; PYRIDOSTIGMINE; STEROID;

ABDOMINAL CRAMP; ADJUVANT THERAPY; AGRANULOCYTOSIS; ANEMIA; BONE DISEASE; BONE MARROW SUPPRESSION; BRAIN LYMPHOMA; CATARACT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HAND TREMOR; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTENSION; INFECTION; INSOMNIA; KIDNEY FUNCTION; LEUKOPENIA; LIVER TOXICITY; MONOTHERAPY; MYASTHENIA GRAVIS; NAUSEA; NEOPLASM; NEPHROTOXICITY; PANCYTOPENIA; PLASMAPHERESIS; POLYMYOSITIS; RELAPSE; REMISSION; REVIEW; SEPSIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SYNCOPE; TERATOGENICITY; THYMECTOMY; TREMOR; URINARY TRACT INFECTION; VALVULAR HEART DISEASE; VIRUS INFECTION; VOMITING; WEIGHT;

EID: 60249088589     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s3309     Document Type: Review

References (30)

1. Allison A. 2005. Mechanisms of action of mycophenolate mofetil. Lupus, 14(Suppl 1):s2-8.
2. Allison A, Eugui EM. 2005. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation, 80(2 Suppl):S181-90.
3. Amato AA, Griggs, R.C. 2003, Treatment of idiopathic inflammatory myopathies, Current opinion in neurology, 16(5): pp 569-75.
4. Cahoon WD Jr, Kockler DR. 2006. Mycophenolate mofetil treatment of myasthenia gravis. Ann Pharmacother, 40:295-8.
5. Chan JW. 2008. Mycophenolate mofetil for ocular myasthenia. J Neurol, 255:510-3.
6. Chaudhry V, Cornblath DR, Griffin JW, et al. 2001. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology, 56:94-6.
7. Ciafaloni E, Massey JM, Tucker-Lipscomb B, et al. 2001. Mycophenolate mofetit for myasthenia gravis: an open-label pilot study. Neurology, 56:97 9.
8. Ciafaloni E. 2005. Myeophenolate mofetil and myasthenia gravis. Lupus, 14(Suppl 1):s46-9.
9. Draper HM. 2008. Depressive disorder associated with mycophenolate mofetil. Pharmacotherapy, 28:136-9.
10. Enk AH, Knop J. 1997. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet, 350:494.
11. Epinette WW, Parker CM, Jones EL. et al. 1987. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol, 17:962-71.
12. European Mycophenolate Mofetil Cooperative Study Group. 1995. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet, 345:1321-5.
13. Hauser RA, Malek AR, Rosen R. 1998, Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology, 51:912-3.
14. Larkin G, Lightman S. 1999. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology, 106:370-4.
15. Levin N, Mali A, Karussis D. 2005. Severe skin reaction related to mycophenolate mofetil for myasthenia gravis. Clin Neuropharmacol, 28:152-3.
16. Lim AK, Donnan G, Chambers B, Ierino FL. 2007. Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity. Int Med J, 37:55-9.
17. Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. 2003. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology, 61: 1438-40.
18. Meriggioli MN, Rowin J, Richman JG, et al. 2003. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci, 998:494-9.
19. Meriggioli MN, Rowin J. 2000. Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Muscle Nerve, 23:1287-9.
20. Meriggioli MN, Rowin J. 2003. Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial. J Clin Neurophysiol, 20:382-5.
21. Neurath MF, Wanitschke R, Peters M, et al. 1999. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut, 44:625-8.
22. Nowack R, Gobel U, Klooker P, et al. 1999. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol, 10:1965-71.
23. Prakash KM, Ratnagopal P, Puvanendran K, et al. 2007. Mycophenolate mofetil - as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience. J Clin Neurosci, 14:278-81.
24. Rozen TD. 2004, Complete but transient relief of chronic cluster headache with mycophenolate mofetil. Headache, 44:818-20.
25. Sanders DB, Hart IK, Mantegazza R, et al. 2008. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis, Neurology, 71:401-6.
26. Schneider C, Gold R, Reiners K, et al. 2001, Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur Neurol, 46:79-82.
27. Schneider-Gold C, Hartung HP, Gold R. 2006. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve, 34:284-91.
28. Sommer, N, Sigg, B, Melms, A, et al. 1997. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry, 62:156-62.
29. The Muscle Study Group. 2008. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology, 71:394-9.
30. Vernino S, Salomao DR, Habermann TM, et al. 2005. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology, 65:639-41.